Abstract: Drug-delivery device for releasing a drug at a continuous and controlled rate for a prolonged period of time is comprised of a shaped body of polymeric material containing a pharmaceutically acceptable drug and permeable to passage of the drug by diffusion. The polymeric material is an ethylene-vinyl acetate copolymer having a vinyl acetate content of about 4 to 80% by weight and a melt index of about 0.1 to 1000 grams per 10 minutes.
Abstract: Novel alkyl diethers of prostaglandins of the formula; ##STR1## wherein R.sub.1 is hydrogen or lower alkyl; R.sub.2 and R.sub.6 are hydrogen when Y is a single bond and R.sub.2 and R.sub.6 are absent when Y is a double bond; R.sub.3 is keto, ##STR2## R'.sub.9 is hydrogen or lower alkyl; R'.sub.10 is lower alkyl; R'.sub.11 is lower alkyl; Z.sub.1 is cis or trans --CH.dbd.CH-- or --CH.sub.2 CH.sub.2 --; Z.sub.2 is trans --CH.dbd.CH-- or --CH.sub.2 CH.sub.2 --; X is a single bond or a double bond and X is a single bond when R.sub.4 and R.sub.5 are hydrogen; Y is a single bond or a double bond; n is 1 to 5, m is 0 to 4; and the non-toxic salts. The prostaglandin ethers possess valuable pharmacological properties as modifiers of smooth muscle activity, gastric secretion, blood pressure, lipolysis and the reproductive system. The compounds also induce labor and menses and they can be used for the relief of asthma and nasal congestion.
Abstract: Drug-delivery device for releasing a drug at a continuous and controlled rate for a prolonged period of time is comprised of a shaped body of polymeric material containing a pharmaceutically acceptable drug and permeable to passage of the drug by diffusion. The polymeric material is an ethylene-vinyl acetate copolymer having a vinyl acetate content of about 4 to 80% by weight and a melt index of about 0.1 to 1000 grams per 10 minutes.
Abstract: Novel alkyl diethers of prostaglandins of the formula; ##STR1## wherein R.sub.1 is hydrogen or lower alkyl; R.sub.2 and R.sub.6 are hydrogen when Y is a single bond and R.sub.2 and R.sub.6 are absent when Y is a double bond; R.sub.3 is keto, ##STR2## R.sub.4 is hydrogen or ##STR3## R'.sub.9 is hydrogen or lower alkyl; R'.sub.10 is lower alkyl; R'.sub.11 is lower alkyl; Z.sub.1 is cis or trans --CH.dbd.CH-- or --CH.sub.2 CH.sub.2 --; Z.sub.2 is trans --CH.dbd.CH-- or --CH.sub.2 CH.sub.2 --; X is a single bond or a double bond and X is a single bond when R.sub.4 and R.sub.5 are hydrogen; Y is a single bond or a double bond; n is 1 to 5, m is 0 to 4; and the non-toxic salts. The prostaglandin ethers possess valuable pharmacological properties as modifiers of smooth muscle activity, gastric secretion, blood pressure, lipolysis and the reproductive system. The compounds also induce labor and menses and they can be used for the relief of asthma and nasal congestion.
Abstract: Drug-delivery device for releasing a drug at a continuous and controlled rate for a prolonged period of time is comprised of a shaped body of polymeric material containing a pharmaceutically acceptable drug and permeable to passage of the drug by diffusion. The polymeric material is an ethylene-vinyl acetate copolymer having a vinyl acetate content of about 4 to 80% by weight and a melt index of about 0.1 to 1000 grams per 10 minutes.
Abstract: Novel compounds of the formula ##STR1## wherein R.sub.1 is hydrogen or alkyl, R.sub.2 is hydrogen or acyl, the diastereomers and the pharmaceutically acceptable salts. The compounds are prepared by the hydrogenation and epimerization of naturally occurring inactive prostaglandins and they are useful as antihypertensive agents and as intermediates for preparing other prostaglandins possessing therapeutic properties. SPThis is a continuation, of application Ser. No. 154,193, filed June 17, 1971, now abandoned.
Abstract: Novel compounds of the formulae: ##STR1## wherein R.sub.2 and R.sub.6 are hydrogen when Z.sub.2 is a single bond and when Z.sub.2 is a double bond R.sub.2 and R.sub.6 are absent; R.sub.3 is a keto, ##STR2## R.sub.7 is OH or OR.sub.9 ; R.sub.8 is H or OH; R.sub.9 is acyl or alkoxyalkyl; R.sub.10 is H or ##STR3## Z.sub.1 is --CH.sub.2 CH.sub.2 -- or cis --CH=CH--; Z.sub.2 is a single bond or a double bond; Z.sub.3 is a single bond or a double bond when R.sub.4 and R.sub.5 are hydrogen; Z.sub.4 is --CH.sub.2 CH.sub.2 -- or trans --CH=CH--; Z.sub.5 is --CH.sub.2 CH.sub.2 -- or cis --CH=CH--; n is 2 to 5, m is 1 to 3, and x is 1 to 2. The compounds are useful for regulating blood pressure, for stimulating smooth muscles, for inhibiting gastric secretion and inhibiting platelet aggregation and they possess improved biological stability and enhanced membrane permeability to serve as an in vivo reservoir of the prostaglandin to ensure the biological availability of the prostaglandin.